Mesa Laboratories, Inc. Announces Upsizing and Pricing of Public Offering of Common Stock
Mesa Laboratories, Inc. (NASDAQ: MLAB) announced the pricing of a public offering of 600,000 shares at $225.00 per share, aiming for gross proceeds of approximately $135 million. A 30-day option for underwriters to purchase an additional 90,000 shares is also granted. The offering, anticipated to settle on June 12, 2020, will fund general corporate purposes, including potential acquisitions. The offering is conducted under a shelf registration statement filed with the SEC.
- Gross proceeds of approximately $135 million will enhance corporate liquidity.
- Intended use of proceeds for acquisitions indicates growth potential.
- Potential dilution of existing shares due to the new offering.
Source: Mesa Laboratories, Inc. - June 9, 2020 8:15 PM ET
Lakewood, Colo., June 09, 2020 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ: MLAB) (“Mesa Labs”) today announced the pricing of an underwritten public offering of 600,000 shares of its common stock at a public offering price of
Mesa Labs intends to use the net proceeds from the offering for general corporate purposes, which may include acquisitions.
Jefferies LLC, J.P. Morgan and Evercore Group L.L.C. are acting as joint book-running managers for the offering.
The offering is being made pursuant to Mesa Labs’ shelf registration statement (including a base prospectus) and a preliminary prospectus supplement (together with such base prospectus, the “prospectus”), all of which Mesa Labs filed with the Securities and Exchange Commission (the “SEC”). Mesa Labs will file with the SEC the final prospectus supplement related to the offering. Before investing in Mesa Labs’ common stock, investors should read the prospectus, including the documents incorporated by reference therein, and any free writing prospectus related to the offering. These documents may be freely obtained by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, copies may be obtained, when available, from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com, or from J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204, or by email at prospectus-eq_fi@jpmchase.com, or from Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, or by telephone at (888) 474-0200, or by email at ecm.prospectus@evercore.com.
This press release does not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any offer or sale of, the shares in any state or jurisdiction in which the offer, solicitation, or sale of the shares would be unlawful prior to the registration or qualification thereof under the securities laws of any such state or jurisdiction.
About Mesa Laboratories, Inc.
Mesa Labs is a multinational manufacturer, developer, and marketer of quality control products and services. The company offers products and services through four divisions: Sterilization and Disinfection Control, Biopharmaceutical Development, Instruments, and Continuous Monitoring. Mesa Labs is headquartered in Lakewood, Colorado, with operations in six countries and sales globally.
Cautionary Language Concerning Forward-Looking Statements
This press release contains forward-looking statements regarding our future business expectations, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding the completion of the proposed offering and the anticipated use of proceeds of the proposed offering, constitute forward-looking statements identified by words like “believe,” “expect,” “may,” “will,” “should,” “seek,” “anticipate,” or “could” and similar expressions. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, uncertainties related to market conditions and the completion of the offering on the anticipated terms or at all. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Mesa Labs’ most recent Annual Report on Form 10-K on file with the SEC and the other reports that Mesa Labs periodically files with the SEC. Actual results may differ materially from those Mesa Labs contemplated by these forward-looking statements. These forward-looking statements reflect management’s current views, and Mesa Labs does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date hereof except as required by law.
Contact: Gary Owens, President and CEO John Sakys, CFO both of Mesa Laboratories, Inc. 303-987-8000
FAQ
What is the recent public offering by Mesa Laboratories (MLAB)?
When is the expected settlement date for the Mesa Laboratories offering?
What are the intended uses of proceeds from the Mesa Laboratories stock offering?
Who are the underwriters for Mesa Laboratories' public offering?
How many additional shares can the underwriters purchase from Mesa Laboratories?
